{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:43:36Z","timestamp":1785473016102,"version":"3.56.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":665,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) reduce morbidity and mortality for heart failure (HF) patients and are recommended as cornerstones for their medical therapy. Utilization in clinical practice remains low for multiple reasons, one of which may be adverse events. We investigated the incidence of these events to see if they are associated with SGLT2i use. A systematic search was performed in databases, including PubMed, Embase, Cochrane Library, Clinicaltrials.gov, and WHO's International Clinical Trials Registry Platform. Relevant randomized controlled trial studies assessing the safety outcomes of SGLT2i in HF patients were included in this study. We conducted the common-effect meta-analysis to estimate the relative risk (RR) and 95% confidence interval (CI) of safety outcomes in SGLT2i compared with placebo. Eighteen studies were included in the meta-analysis composed of 12 925 HF patients taking an SGLT2i and 12 747 taking a placebo. The meta-analysis indicated that the all-cause mortality and serious adverse events (SAEs) were lower in the SGLT2i group (RR, 0.91; 95% CI, 0.85\u20130.97; P = 0.005, I2 = 0%; and RR, 0.92; 95% CI, 0.90\u20130.95; P &amp;lt; 0.001, I2 = 43%, respectively). Volume depletion and genitourinary infections were more prevalent in the SGLT2i group (RR, 1.17; 95% CI, 1.06\u20131.28; P = 0.001, I2 = 0%; and RR, 1.27; 95% CI, 1.13\u20131.43; P &amp;lt; 0.001, I2 = 17%, respectively). Our meta-analysis demonstrated that using SGLT2is in HF patients was correlated with reduced mortality and SAEs, with a more prominent effect in HF with reduced ejection fraction patients and those taking dapagliflozin.<\/jats:p>","DOI":"10.1002\/ehf2.14633","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T23:56:32Z","timestamp":1703116592000},"page":"637-648","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of Sodium-Glucose Cotransporter 2 Inhibitors Drugs Among Heart Failure Patients: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"11","author":[{"given":"Hamidreza","family":"Soleimani","sequence":"first","affiliation":[{"name":"Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrad","family":"Saeedian","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeganeh","family":"Pasebani","sequence":"additional","affiliation":[{"name":"Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Babajani","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza Pashapour","family":"Yeganeh","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Bahirai","sequence":"additional","affiliation":[{"name":"Shahid Beheshti University of Medical Science , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Navid","sequence":"additional","affiliation":[{"name":"Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Amin","sequence":"additional","affiliation":[{"name":"Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Samsky","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal G.","family":"Nanna","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"2026012113160289600_ehf214633-bib-0001","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012113160289600_ehf214633-bib-0002","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113160289600_ehf214633-bib-0003","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jchf.2023.03.024","article-title":"Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: Insights from the Department of Veterans Affairs","volume":"11","author":"Hussain","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113160289600_ehf214633-bib-0004","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12877-019-1110-6","article-title":"The burden of health conditions for middle-aged and older adults in the United States: Disability-adjusted life years","volume":"19","author":"McGrath","year":"2019","journal-title":"BMC Geriatr"},{"key":"2026012113160289600_ehf214633-bib-0005","doi-asserted-by":"publisher","first-page":"157","DOI":"10.18553\/jmcp.2022.28.2.157","article-title":"Burden of hospitalization for heart failure in the United States: A systematic literature review","volume":"28","author":"Osenenko","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026012113160289600_ehf214633-bib-0006","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113160289600_ehf214633-bib-0007","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113160289600_ehf214633-bib-0008","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113160289600_ehf214633-bib-0009","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113160289600_ehf214633-bib-0010","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jchf.2023.05.006","article-title":"Overcoming barriers to use of SGLT2 inhibitor therapy: The battle against clinical inertia","volume":"11","author":"Greene","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113160289600_ehf214633-bib-0011","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030876","article-title":"Predictors and outcomes of SGLT2 inhibitor discontinuation in a real-world population after hospitalization for heart failure","volume":"11","author":"Nakagaito","year":"2023","journal-title":"Biomedicine"},{"key":"2026012113160289600_ehf214633-bib-0012","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"2026012113160289600_ehf214633-bib-0013","author":"PROSPERO"},{"key":"2026012113160289600_ehf214633-bib-0014","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026012113160289600_ehf214633-bib-0015","author":"Cochrane Bias Methods G"},{"key":"2026012113160289600_ehf214633-bib-0016","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"2026012113160289600_ehf214633-bib-0017","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2026012113160289600_ehf214633-bib-0018","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026012113160289600_ehf214633-bib-0019","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026012113160289600_ehf214633-bib-0020","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026012113160289600_ehf214633-bib-0021","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026012113160289600_ehf214633-bib-0022","doi-asserted-by":"publisher","first-page":"783","DOI":"10.11909\/j.issn.1671-5411.2021.10.003","article-title":"Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: A meta-analysis of randomized clinical trials","volume":"18","author":"Bazoukis","year":"2021","journal-title":"J Geriatr Cardiol"},{"key":"2026012113160289600_ehf214633-bib-0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100690","article-title":"Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis","volume":"32","author":"Chambergo-Michilot","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026012113160289600_ehf214633-bib-0024","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026012113160289600_ehf214633-bib-0025","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40256-020-00441-x","article-title":"Effects of dapagliflozin on cardiovascular events, death, and safety outcomes in patients with heart failure: A meta-analysis","volume":"21","author":"Zheng","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026012113160289600_ehf214633-bib-0026","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: Systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012113160289600_ehf214633-bib-0027","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: A meta-analysis of randomized clinical trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am J Med"},{"key":"2026012113160289600_ehf214633-bib-0028","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2021.03.077","article-title":"Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials","volume":"332","author":"Li","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026012113160289600_ehf214633-bib-0029","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026012113160289600_ehf214633-bib-0030","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026012113160289600_ehf214633-bib-0031","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"2026012113160289600_ehf214633-bib-0032","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"2026012113160289600_ehf214633-bib-0033","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"2026012113160289600_ehf214633-bib-0034","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ehf2.12345","article-title":"Empagliflozin, calcium, and SGLT1\/2 receptor affinity: Another piece of the puzzle","volume":"5","author":"Anker","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012113160289600_ehf214633-bib-0035","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00392-021-01913-z","article-title":"Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: A systematic review and head-to-head comparative efficacy network meta-analysis","volume":"111","author":"T\u00e4ger","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"2026012113160289600_ehf214633-bib-0036","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"key":"2026012113160289600_ehf214633-bib-0037","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1253\/circrep.CR-19-0070","article-title":"Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus","volume":"1","author":"Nakagaito","year":"2019","journal-title":"Circ Rep"},{"key":"2026012113160289600_ehf214633-bib-0038","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2133\/dmpk.dmpk-12-rg-082","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects","volume":"28","author":"Sarashina","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"2026012113160289600_ehf214633-bib-0039","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.clinthera.2015.06.003","article-title":"Pharmacokinetics and pharmacodynamics of twice daily and once daily regimens of empagliflozin in healthy subjects","volume":"37","author":"Macha","year":"2015","journal-title":"Clin Ther"},{"key":"2026012113160289600_ehf214633-bib-0040","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/dme.13629","article-title":"Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with type 2 diabetes: A randomized trial","volume":"35","author":"Laffel","year":"2018","journal-title":"Diabet Med"},{"key":"2026012113160289600_ehf214633-bib-0041","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026012113160289600_ehf214633-bib-0042","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"2026012113160289600_ehf214633-bib-0043","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: Results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2026012113160289600_ehf214633-bib-0044","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/637\/64540316\/eschf_11_2_637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/637\/64540316\/eschf_11_2_637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:18:05Z","timestamp":1769019485000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/2\/637\/8271358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14633","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"2023-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}